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Abstract
Background: The cyclin-dependent kinase 2 (CDK2) together with its cyclin E and A partners is a central regulator of
cell growth and division. Deregulation of CDK2 activity is associated with diseases such as cancer. The analysis of
substrates identified S/T-P-X-R/K/H as the CDK2 consensus sequence. The crystal structure of cyclin A/CDK2 with a
short model peptide supports this sequence and identifies key interactions. However, CDKs use additional
determinants to recognize substrates, including the RXL motif that is read by the cyclin subunits. We were interested to
determine whether additional amino acids beyond the minimal consensus sequence of the well-studied substrate and
tumor suppressor p27KIP1 were relevant for catalysis.
Results: To address whether additional amino acids, close to the minimal consensus sequence, play a role in binding,
we investigate the interaction of cyclin A/CDK2 with an in vivo cellular partner and CDK inhibitor p27KIP1. This protein is
an intrinsically unfolded protein and, in particular, the C-terminal half of the protein has not been accessible to
structural analysis. This part harbors the CDK2 phosphorylation site. We used bioinformatics tools, including MODELLER,
iTASSER and HADDOCK, along with partial structural information to build a model of the C-terminal region of p27KIP1
with cyclin A/CDK2. This revealed novel interactions beyond the consensus sequence with a proline and a basic amino
acid at the P + 1 and the P + 3 sites, respectively. We suggest that the lysine at P + 2 might regulate the reversible
association of the second counter ion in the active site of CDK2. The arginine at P + 7 interacts with both cyclin A and
CDK2 and is important for the catalytic turnover rate.
Conclusion: Our modeling identifies additional amino acids in p27KIP1 beyond the consensus sequence that contribute
to the efficiency of substrate phosphorylation.
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Background
Cell cycle progression is controlled by cyclin-dependent
kinases (CDK) complexes. CDK2 in complex with E type
cyclins regulates the transition through the restriction
point in the G1 phase of the cell cycle and early events
in S phase. A major function of cyclin A/CDK2
complexes is to promote DNA replication and the pro-
gression though S phase [1]. Consistent with these im-
portant functions are the involvement of CDK2 kinase
complexes in diseases, including cancer [2]. Different
cyclins are overexpressed while the expression of CDK
inhibitors is reduced in different tumor entities [2].
These findings suggest that CDKs are promising targets
for pharmaceutical interventions and CDK2 inhibitors
are in clinical trials [3–5]. Moreover, Wee1, a tyrosine
kinase repressor of CDK1 and CDK2, is targeted by
small molecules to prevent repression of CDK1 and
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CDK2 in response to DNA damage and thus enhance
genetic instability and apoptosis [6]. Thus the activation
or repression of these CDKs is potentially beneficial to
cancer patients dependent on the nature of the tumor
[7]. Together, these findings suggest that the molecular
understanding of the catalytic function of these kinases
is both of fundamental and clinical relevance.
In general, cyclin/CDK2 complexes phosphorylate sub-
strate proteins at S or T residues (the so-called P + 0 site,
single amino acid code is used). Early on it was recog-
nized that these kinases prefer S/T sites that are followed
by a proline (at the P + 1 site) [8], an amino acid that is
conserved across nearly all cyclin/CDK substrates. The
use of oriented peptide libraries in kinase assays with
cyclin A/CDK2 resulted in the description of HHASPRK
as an optimal substrate peptide [9], with a basic residue
frequently observed at the P + 3 site [9, 10]. This was
used to obtain structural information of the cyclin A/
CDK2 complex bound to a substrate peptide [11], sup-
porting the conclusion that the amino acids at positions
P + 0, P + 1 and P + 3 (underlined in HHASPRK) are rec-
ognized by the enzyme.
The above summarized findings relate to a rather
small peptide. Whether such a sequence is sufficient for
mediating phosphorylation in cells is not known. Fre-
quently multiple lower affinity interactions contribute to
functional specificity [12, 13]. One such motif for at least
some cyclin/CDK complexes is the RXL sequence on
substrates. Cyclin A can interact with this short se-
quence motif, which enhances specificity beyond the se-
quence recognized by the kinase domain, and was found
to be important to mediate CDK2 phosphorylation [14].
Moreover, it is feasible that also the short sequence
motif found to interact with the catalytic domain, which
is characterized by a P at the P + 1 and a basic amino
acid at the P + 3 site, is further expanded and thus might
offer additional selectivity.
Defining interaction domains of substrates, beyond
their minimal peptide sequence, with their enzymes al-
lows more detailed molecular analysis. Of interest is to
understand whether CDK2 recognizes its substrates by a
common binding mode beyond the consensus sequence
S/T-P-X-R/K/H described above. Thus, do longer pep-
tide chains, as present in real proteins, affect binding
and phosphorylation? To know more about the inter-
action of CDK2 with a substrate is also indicated as
CDK2 inhibitors are evaluated as therapeutic tools in
clinical trials [7]. More detailed knowledge of enzyme-
substrate interaction may allow defining more selective in-
hibitors beyond ATP analogs. Here we address this issue
by using homology modeling, docking, and bioinformatics
conservation analyses and biochemical methods. We focus
on the tumor suppressor p27KIP1, whose cyclin E/CDK2
and cyclin A/CDK2-dependent phosphorylation results in
subsequent degradation [15, 16]. We observe that add-
itional interactions of p27KIP1 with CDK2 are relevant to
enhance phosphorylation rates.
Results and Discussion
Consensus sequences of CDK2 substrates
The majority of information on substrate sequences for
CDK2 has been obtained from analyzing peptide and
protein substrates using in vitro kinase assays. We
wanted to define whether the CDK2 consensus substrate
sequence extends beyond the S/T-P-X-R/K/H motif
when sites that were confirmed in cells were used. We
used PhosphoSitePlus [17] to define potential CDK2
substrates. We then screened the relevant publications i)
for direct phosphorylation of the substrate by cyclin/
CDK2 including mapping of the site phosphorylated in
vitro, ii) for phosphorylation of this site in cells using
mass spectrometry and/or phosphospecific antibodies,
and iii) for altered phosphorylation of this site in re-
sponse to modulating CDK2 activity by genetic means
or for phosphorylation in a cell cycle-dependent manner
that is consistent with CDK2 activity. Thirty-five CDK2
sites of a total of 27 substrates fulfilled these criteria
(Table 1). Sequence logo analysis of these CDK2 sites
suggested that the S/T-P motif is invariable and that
nearly 80% of the substrates possess a basic amino acid
at P + 3 (Fig. 1). Thus, most substrates fulfill the require-
ments of the consensus sequence obtained by using pep-
tide substrates. Little preference for other amino acids at
any other position was detected. This is consistent with
the concept that additional determinants of various na-
ture, including the RXL motif [14], might contribute to
the substrate specificity in cells [13]. Moreover, add-
itional amino acids in the sequence that is modified and
that is recognized near the catalytic cleft may contribute
to selectivity. Together several different weak determi-
nants may contribute to the overall affinity of an individ-
ual substrate and thus contribute to the efficiency of
phosphorylation.
Structural model of a p27KIP1 substrate peptide with
cyclin A/CDK2
We have addressed the role of additional amino acids
close to the consensus sequence for the tumor suppres-
sor p27KIP1, one of the best-studied substrates of CDK2
complexes. p27KIP1 functions as an inhibitor of CDK2
and CDK1 complexes and thus has the ability to inter-
fere with cell cycle progression, for example in response
to anti-proliferative signals [16]. p27KIP1 is a naturally
unfolded protein that is largely disordered in solution
[18–20]. Thus, determining its conformation based on
computational methods is currently very challenging.
In complex with cyclin A/CDK2, the N-terminal por-
tion of p27KIP1 (amino acids 25–93) assumes a stable
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conformation. In the co-crystal of cyclin A/CDK2—p27KIP1
two binding regions in the latter were identified [21].
Amino acids 25–50 of p27KIP1 interact with cyclin A,
whereas amino acids 52–93 bind to CDK2. This second
interaction region includes the so-called 310 helix,
which contains Y88 (for a structure-function compari-
son of p27KIP1 see Fig. 2a). Y88 is substrate of non-
receptor tyrosine kinases [22]. Y88 phosphorylation
triggers a conformational transition and ejects the
p27KIP1 310 helix from the CDK2 catalytic cleft [23, 24].
This in turn allows the binding of the C-terminal part of
p27KIP1 and the subsequent phosphorylation of T187 by
CDK2 [22]. This site is part of the CDK2 consensus
sequence with T187PKK in p27
KIP1.
No structural information is presently available for the
C-terminal half of p27KIP1 (residues 91–198). There are
two main strategies for structural predictions of protein
complexes [25]. Template-based docking is a high-
throughput method, which performs fairly well when
using with high- and medium-sequence or structural
similarity (root-mean-square deviation, RMSD <6 Å) be-
tween template and target. This is not the case for
CDK2 substrates as the peptide (HHASPRK) in the only
available crystal structure of a cyclin A/CDK2/substrate
complex is not large enough to provide sufficient infor-
mation of the protein-protein interface for template-
based docking [11]. Because of this, free docking is the
method of choice with the interacting proteins using the
available experimental constraints. As pointed out above,
p27KIP1 is disordered and no structural information is
available, specifically of the C-terminal half of the pro-
tein that contains the cyclin A/CDK2 phosphorylation
site. The occurrence of disordered regions for kinase
substrates is common, because kinases normally phos-
phorylate sites in less ordered regions that are exposed
on the surface of proteins [26–28]. Hence, we applied
homology modeling, along with existing information of
identical short amino acid sequences with known struc-
tures, to construct structural models of the interactor
[11, 29]. The docking was guided by two key observa-
tions. First, the phosphorylation site of the substrate
forms an H-bond with ATP [11]. Second, the basic resi-
due at the P + 3 site forms H-bonds to the phosphory-
lated T160 (pT160) of CDK2 and I270 of cyclin A [11].
Phosphorylation of T160 in the activation loop is critical
for catalytic activity of CDK2 [30]. Consistent with a role
of this kinase in late G1, S and G2, phosphorylation of
T160 is high in these phases of the cell cycle [31].
The p27KIP1 peptide (amino acids 180 to 194) adopted
an extended conformation in the active site of CDK2
(Fig. 2b and c). The interactions that were noticed be-
tween CDK2 and the substrate in the crystalized cyclin
A/CDK2/HHASPRK structure [11] and in the modeled
cyclin A/CDK2/SIRT2 complex [32] are maintained. The
positions of T187 and P188 are very similar in our
model to those in the cyclin A/CDK2/HHASPRK struc-
ture (Fig. 3). The T187, the P + 0 site amino acid, inter-
acts with ATP through an H-bond. More C-terminal the
structures start to deviate clearly seen with K190, which
moves considerably due to the additional amino acids in
the p27KIP1 peptide (amino acids 180 to 194) but still in-
teracts with pT160 of CDK2 and I270 of cyclin A
(Figs. 2c and 3).
Table 1 Information on human CDK2 substrates confirmed by
in vivo experiments
Index Protein UniProtKB P + 0 site Site sequence Ref.
1 ATRIP Q8WXE1 S224 VSHVSPRKNPSV [50]
2 BRCA1 P38398 S1497 VERSSPSKCPSL [51]
3 CDKN2D P55273 S76 SGTSPVHDAAR [52]
4 CROCC iso2 Q5TZA2-2 S763 PVPGSPARDAPA [53]
5 Ctip Q99708 T847 IPPNTPENFWEV [54]
6 DLG1 Q12959 S158 HSHISPIKPTEA [55]
7 Q12959 S443 QTPASPARYSPV
8 EZH2 Q15910 T345 ERIKTPPKRPGG [56]
9 FOXM1 iso2 Q08050-2 T596 PISSTPSKSVLP [57]
10 FOXO1A Q12778 S249 KSGKSPRRRAAS [58]
11 HIRA P54198 T555 SVLTTPSKIEPM [59]
12 HR6A P49459 S120 PNPNSPANSQAA [60]
13 ID3 Q02535 S5 MKALSPVRGCYE [61]
14 ING5 Q8WYH8 T152 EEEDTPKKKKHK [62]
15 LIG3 P49916 S210 GQVTSPVKGASF [63]
16 ORC2 Q13416 T116 ELAKTPQKSVSF [64]
17 Q13416 T226 VGKETPSKRMKR
18 p27 P46527 T187 SVEQTPKKPGLR [65]
19 p63 Q9H3D4 T491 RNALTPTTIPDG [66]
20 p73 O15350 T86 ASPYTPEHAASV [67]
21 PELP1 Q8IZL8 S991 PPPESPPKVQPE [68]
22 PLZF Q05516 S197 LSAMSPTKAAVD [69]
23 Q05516 T282 EGPGTPTRSSVI
24 PTPN2 iso2 P17706-2 S304 AFDHSPNKIMTE [70]
25 RbBP1 P29374 S864 LGQSSPEKKIRI [71]
26 P29374 S1007 FSVASPLTLSQD
27 RPL12 P30050 S38 PLGLSPKKVGDD [72]
28 SIRT2 Q8IXJ6 S368 STSASPKKSPPP [49]
29 Smad3 P84022 T8 ILPFTPPIVKRL [73]
30 P84022 T179 NIPETPPPGYLS
31 P84022 S213 PNPMSPAHNNLD
32 SMRT Q9T618 S1259 IGEDSPSRLDRG [74]
33 Q9T618 T1463 ITQGTPLKYDTG
34 Q9T618 S1487 SLIGSPGRTFPP
35 NBS1 Q9NX02 S432 NYQLSPTKLPSI [75]
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Lysine at the P + 2 site and turnover rate
In contrast to the crystal structure [11], in which the ar-
ginine at the non-conserved P + 2 site does not have any
contact with cyclin A/CDK2, the lysine at the P + 2 site
of p27KIP1 (K189) forms a salt bridge with ATP and an
H-bond with T14 of CDK2 (Fig. 2c). The first cyclin A/
CDK2 structure solved contained one metal ion as part
of the ATP · Mg2+ cofactor complex [11, 33], while many
other kinases contain two. In a more recent study, a cyc-
lin A/CDK2 transition state complex with ADP, MgF3
– (a
mimic for the γ-phosphate in the transition state), and a
short peptide was crystallized, which revealed a second
Mg2+ ion [34]. Based on this structure, a mechanistic
analysis suggested that CDK2 also uses 2 Mg2+ ions [35].
The second Mg2+ ion appears to associate reversibly
with the active site. It is required just before the chem-
ical step of the catalytic cycle and dissociates as soon as
the reaction is complete. Thus, it promotes efficient
phosphoryl transfer. But this second Mg2+ ion also in-
creases, together with the other Mg2+ ion, the affinity of
Fig. 1 Sequence logo plot represent normalized amino acid frequencies for ±7 amino acids from the phosphorylation site of CDK2 in vivo
substrates reported in Table 1. This figure was generated using WebLogo [76]
Fig. 2 Schematic visualization of p27KIP1 and structural model of the cyclin A/CDK2/p27KIP1 peptide (amino acids 180–194) complex. a Schematic
representation of the domain organization of p27KIP1. The N-terminal segment (NTS, residues 1–28), the N-terminal kinase inhibitory domain (KID,
residues 28–90), the C-terminal region (CT, residues 91–198), and the nuclear localization sequence (NLS, residues 152–169) are indicated. The
known phosphorylation sites observed in p27KIP1 are also indicated [15]. The cyclin and CDK2 binding regions in KID are highlighted
[21]. The available crystal structure data for p27KIP1 are highlighted by black bars (PDB ID: 1JSU (residues 25–93) [21] and 2AST (residues
181–190) [29]). The C-terminal binding region (residues 180–194), for which a structural model was constructed, is indicated by a dashed
box. b The overall structure is shown in cartoon representation. CDK2, cyclin A, and the peptide substrate (amino acids 180–194 of p27KIP1) are colored
in blue, orange, and green, respectively. The model contains ATP. c Close-up view of the binding interface between p27KIP1 and cyclin
A/CDK2. Hydrogen bonds are highlighted in black dashed lines. d Sequence alignment showing the conservation of E42 in CDK2
compared with other CDKs. The sequence alignment was obtained using the Clustal Omega webserver [42]. Identical and structurally
similar residues are indicated in red and green, respectively
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ADP and it therefore prevents efficient release. This
would reduce the overall turnover rate of the enzymatic
reaction [35]. Keeping this in mind, we compared our
model with the crystal structure of protein kinase A
(PKA) [36]. We observed that the location of the posi-
tively charged nitrogen atom of K189 of p27KIP1 is simi-
lar to that of the second metal ion in PKA (Fig. 4). We
speculate that K189 and its positive charge may affect
the stability and/or the positioning of the second Mg2+
ion and facilitate its release once the phosphoryl transfer
is completed. In consequence this may result in an ac-
celeration of the turnover rate. In support of this model,
short CDK2 substrate peptides with K or R at the P + 2
position show the highest velocity of phosphoryl transfer,
while acidic amino acids reduce velocity considerably [10].
Together these findings indicate that the second Mg2+ ion
promotes catalysis and in combination with a basic
residue at the P + 2 site of the substrates the price for a
reduced turnover rate does not have to be paid [37].
Specific contacts of the P + 7 arginine of the substrate
peptide with cyclin A/CDK2
Additional contacts were identified in our model of the
trimeric cyclin A/CDK2/p27KIP1 peptide (amino acids
180-194) complex between the non-consensus part of
p27KIP1 and cyclin A/CDK2. S183 and G182 of the
p27KIP1 peptide make H-bonds with the active site resi-
dues Q131 and K88 of CDK2, respectively (Fig. 2c). Im-
portantly, R194 of p27KIP1 forms H-bonds with E42 of
CDK2 and P272 of cyclin A, both of which are located at
the binding interface between CDK2 and cyclin A. This
glutamate is conserved across CDK2, CDK3, CDK5 and
CDK6 and belongs to the extension loop of the PSTAIRE
helix of CDK2 (residues 45–51) (Fig. 2d), which shows the
most significant movement upon cyclin A binding [33].
Thus, R194 may play a role in the phosphorylation of
p27KIP1 by cyclin A/CDK2 through interacting with and
altering the position of the extended PSTAIRE loop. This
might stabilize the active cyclin A/CDK2 complex.
Arginine at the P + 7 position enhances the enzymatic
turnover rate
To validate our model, we performed in vitro kinase assays.
A p27KIP1 wild-type (wt) peptide (amino acids 180 to 194)
and a peptide with an R194A substitution were synthesized
and their capacity to be phosphorylated by cyclin A/CDK2
was evaluated. We determined the kinetic constants for
these synthetic peptides. The KM values of the two peptides
were very similar with 93.6 and 81.4 μM for the wt and
R194A, respectively (Fig. 5 and Table 2). However, we ob-
served a difference in the maximal relative rate of phos-
phoryl transfer between the two peptides, i.e. 2.21 and 1.11
pmol/min for the wt and the R194A peptide, respectively
(Fig. 5 and Table 2). Thus the turnover rate of the wt pep-
tide was twice as high as of the R194A mutant peptide. It
is possible that the interaction of R194 with both cyclin A
and CDK2 allows a faster correct orientation of the P + 0
site amino acid T187 in the catalytic cleft. This data sug-
gests that beside the core consensus sequence defined by
the HHASPRK peptide additional residues can be involved
in determining the efficiency of substrate phosphorylation.
Conclusions
The minimal consensus sequence for CDK2 and several
other CDKs matches the sequence S/T-P-R/K/H. This
information is mainly drawn from work with short
model peptides as substrates [9–11]. To increase specifi-
city of an enzyme-substrate interaction, additional deter-
minants are required, which may be distinct between
Fig. 3 Superposition of the predicted model of cyclin A/CDK2/p27KIP1
with cyclin A/CDK2/HHASPRK X-ray structure (PDB ID: 1QMZ [11]). The
cartoon representations of CDK2, cyclin A, and the p27KIP1 peptide
(amino acids 180–194) are colored in blue, orange, and green, respectively.
The peptide substrate in the crystal structure is colored in cyan
Fig. 4 Superposition of cyclin A/CDK2/p27KIP1 peptide (amino acids
180–194) with the PKA/ATP/2 Mn2+ crystal structure (PDB ID: 1AST [36]).
The second Mn2+ in PKA is indicated by cyan sphere. The cartoon
representations of CDK2 and p27KIP1 are colored in blue and green,
respectively. PKA is colored in cyan. PKA residues are labeled with prime
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substrates. In more general terms it has been argued that
during evolution multiple lower affinity interactions have
been selected to contribute to functional specificity [12,
13]. Intuitively, one might expect that systems develop
towards high affinity interactions. However, this seems
not to be the case. In fact, signaling, and thus the flow
of information, often involves non-structured parts of
proteins and low affinity interaction. Nevertheless, these
processes are remarkably specific and functional. More-
over, proximity is another important aspect to create
specificity [38]. This may include the use of scaffold pro-
teins, targeting subunits or specific microenvironments
that allow the co-localization of proteins. All these as-
pects contribute to the substrate specificity of enzymatic
reactions. For example the use of scaffold proteins has
been well documented for the activation of MAP kinases
in different signaling pathways [39]. In some respect
cyclins also have scaffolding function, in addition to acti-
vating the CDK. For some cyclin/CDK complex sub-
strates an RXL motif, which is recognized by the cyclin,
is important for efficient phosphorylation [40]. Here we
identified amino acid P + 7 of the CDK2 phosphorylation
site at T187 in p27KIP1 as important for the phosphoryl
transfer rate. R194 enhances the turnover rate of a pep-
tide substrate compared to a mutant peptide with
R194A. The P + 7 site is not conserved in cellular CDK2
substrates, suggesting that it has a unique effect on
p27KIP1 as a key substrate in the control of cell cycle
progression. In other substrates, other changes may
affect the enzymatic properties and thus, depending on
the specific needs, different alterations in substrates may
contribute to the efficiency of phosphorylation by CDK2.
Moreover, the identification of the amino acid P + 7 of
the substrate as relevant for catalysis suggests that deter-
minants relatively far from the site of modification could
be relevant for interfering with CDK2 activity. Such de-
terminants could contribute to developing more select-
ive inhibitors, which might be relevant in light of the
interest in developing selective CDK inhibitors for thera-
peutic purposes [7].
Methods
Modeling of cyclin A/CDK2/p27KIP1 complexes
Structural predictions of p27KIP1 is challenging because
the protein is largely disordered. In particular no informa-
tion is available for the C-terminal half of the protein. We
constructed models of the C-terminal p27KIP1 peptide
(residues 180–194, sequence N180AGSVEQTPKKPGLR,
see Fig. 2a) based on the X-ray structure of the p27KIP1
peptide A181GSVEQTPKK [29] and the 30S ribosomal
protein S8 peptide K81PGLR [41], of which the sequence
identities to the p27KIP1 peptide are 67% and 33%, respect-
ively (for a flow chart of the procedure, see Fig. 6). 200
Fig. 5 Analysis of cyclin A/CDK2 kinase activity on p27KIP1 substrate
peptides. Cyclin A/CDK2 Kinase purified from Sf9 cells was incubated
with increasing concentrations of p27KIP1 wild type and the R194A
mutant peptide as indicated. Phosphorylation of the peptides was
monitored after immobilisation on SAM2 membrane by scintillation
counting and analysis by GraphPad Prism software. Shown are mean
values ± SD of 5 experiments performed in duplicates
Table 2 Kinetic constants for phosphorylation of p27KIP1
peptides
Peptide Sequence Km [μM] Relative rate
[pmol/min]
Relative rate/Km
wt N180AGSVEQTPKKPGLR 93.6 2.21 0.0195
R194A N180AGSVEQTPKKPGLA 81.4 1.11 0.0135
Fig. 6 Flow chart describing the modeling process as detailed in the
Methods section
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models of the p27KIP1 C-terminal peptide were generated
using the automodel class implemented in MODELLER
9v9 package [42]. Sixty-four models turned out to have
90% or more of the amino acids in the most favored re-
gions of the Ramachandran plot [43]. We selected the
model that showed the lowest difference regarding back-
bone RMSD (1.1 Å) with respect to the C-terminal pep-
tide 180–194 and the crystal structure of amino acids
181–190 of p27KIP1 [29]. This model was also in agree-
ment with an analysis using the iTASSER server [44],
from which we obtained five models. All were in an ex-
tended conformation similar to the results obtained with
MODELLER 9v9 [42] (i.e. backbone RMSD between 0.15
to 0.22 nm, data not shown). The selected model was fur-
ther evaluated by using MolProbity server [45]. The Mol-
Probity score of the model is 97th percentile closing to
100th percentile of the best structure in the dataset, which
shows a good quality of the model. The structure of cyclin
A/CDK2 in complex with ATP ·Mg2+ was obtained from
a previous study [11]. Data-driven docking calculations of
cyclin A/CDK2 with the p27KIP1 peptide was carried out
as described [32]. The model of cyclin A/CDK2 is based
on the X-ray structure of human CDK2 in complex with
cyclin A and the HHASPRK peptide (PDB ID: 1QMZ
[11]). This contains one Mg2+ ion bound to a water mol-
ecule, the ATP cofactor, and N132 and D145 of CDK2. In
the docking calculations, we considered only non-
hydrogen atoms and imposed restraints between the phos-
phorylation site of the substrate and ATP, because the
contact between ATP and the phosphorylation site is the
prerequisite for the phosphoryl group transfer reaction
[46], and between the basic residue at the P + 3 site of the
substrate, pT160 of CDK2, and I270 of cyclin A, because
these contacts are crucial for substrate specificity, as indi-
cated by the crystal structure of cyclin A/
CDK2•HHASPRK [11]. Distance restraints were applied
on Mg2+ ions and their ligands to preserve the coordin-
ation structure using the HADDOCK program [47, 48].
Rigid body docking, semi-flexible simulated annealing and
explicit molecular dynamics refinement implemented in
HADDOCK [47, 48] were carried out with the default pa-
rameters. Hydrogen bonds were defined to be present if
the distance between the acceptor and donor atoms is
below 3.5 Å and the angle among the hydrogen-donor-
acceptor atoms are below 30°. All figures for the
visualization of structures were drawn using PyMOL (Mo-
lecular Graphics System, Version 1.3, Schrödinger LLC).
Protein purification and in vitro kinase assay
Human cyclin A/CDK2 complexes were expressed in
SF9 insect cells (Spodoptera frugiperda) upon infection
with recombinant baculo viruses encoding either cyclin
A or CDK2. The complex was purified using the GST
tag of cyclin A [49]. In vitro kinase assays of cyclin A/
CDK2 were performed in kinase buffer (50 mM Tris-
HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT,
40 mM α-glycero-phosphate, 20 mM p-nitrophenylpho-
sphate, 0.1 mM sodium vanadate, 0.01% BriJ 35) con-
taining 50 μM ATP and 1 μCi 32P-γ-ATP for 10 min at
30°C in the presence of increasing amount of biotinyl-
ated p27KIP1 wild type or R194A (an arginine to alanine
substitution at position 194) peptides as substrates. The
assays were terminated by adding 12.5 μl 7.5 M guan-
idine hydrochloride. The peptides were immobilized on
SAM2 Biotin Capture Membranes (Promega), exten-
sively washed as described in the manufacturer’s proto-
col, and then monitored for radioactivity in a liquid
scintillation counter to calculate the specific kinase ac-
tivity. Kinetic parameters were determined with Graph-
Pad Prism software built-in “Enzyme kinetic Michaelis-
Menten”. The sequence of the p27KIP1 wild type peptide
corresponds to amino acids 180 to 194. The peptides
were synthesized with a biotin-PEG-20-linker and puri-
fied by HPLC at the Peptide Specialty Laboratories,
Heidelberg (Germany).
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